| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/29/2006 | CA2591889A1 Treatment for severe melancholic depression with epa |
| 06/29/2006 | CA2591817A1 Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| 06/29/2006 | CA2591810A1 Chroman derivatives and uses thereof in the treatment of cns disorders |
| 06/29/2006 | CA2591800A1 Tetralin and indane derivatives and uses thereof as 5-ht antagonists |
| 06/29/2006 | CA2591793A1 Tetralin and indane derivatives and uses thereof |
| 06/29/2006 | CA2591768A1 Cancer specific antibody and cell surface proteins |
| 06/29/2006 | CA2591766A1 Tetrahydroquinoline analogues as muscarinic agonists |
| 06/29/2006 | CA2591757A1 Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazine |
| 06/29/2006 | CA2591746A1 Macrolides |
| 06/29/2006 | CA2591744A1 Stable non-dihydrate azithromycin oral suspensions |
| 06/29/2006 | CA2591706A1 Pharmaceutical formulations |
| 06/29/2006 | CA2591705A1 Novel farnesyl protein transferase inhibitors as antitumor agents |
| 06/29/2006 | CA2591665A1 Binding molecules capable of neutralizing west nile virus and uses thereof |
| 06/29/2006 | CA2591217A1 Painkilling association comprising a dihydroimidazopyrazine derivative |
| 06/29/2006 | CA2591215A1 Cdc25 phosphatase inhibitors |
| 06/29/2006 | CA2591212A1 Use of a dihydroim1dazopyrazine derivative for treating or preventing pain |
| 06/29/2006 | CA2591208A1 Pyrazines and pyridines and derivatives thereof as therapeutic compounds |
| 06/29/2006 | CA2591129A1 Treatment of inflammatory diseases |
| 06/29/2006 | CA2591125A1 Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists |
| 06/29/2006 | CA2591089A1 Medicaments for the treatment or prevention of fibrotic diseases |
| 06/29/2006 | CA2591084A1 Medicaments for the treatment or prevention of fibrotic diseases |
| 06/29/2006 | CA2591083A1 Medicaments for the treatment or prevention of fibrotic diseases |
| 06/29/2006 | CA2591076A1 Transdermal plaster with progesterone a-specific ligands (prasl) as an active ingredient |
| 06/29/2006 | CA2590985A1 Cycloalkylamine derivatives |
| 06/29/2006 | CA2590957A1 4-aminopiperidine derivatives |
| 06/29/2006 | CA2590912A1 Bicyclic pyrrole derivatives |
| 06/29/2006 | CA2590848A1 Oral immediate release formulation of a poorly water-soluble active substance |
| 06/29/2006 | CA2590742A1 Sulfonamido-macrocycles as tie2 inhibitors |
| 06/29/2006 | CA2590522A1 Sulfonamido-macrocycles as tie2 inhibitors |
| 06/29/2006 | CA2590494A1 Method for the production of oxazoles by condensing aromatic aldehydes with a-ketoximes to n-oxides and then reacting the same with activated acid derivatives |
| 06/29/2006 | CA2590471A1 Combination treatment for multiple sclerosis |
| 06/29/2006 | CA2590254A1 Rapamycin derivatives and the uses thereof in the treatment of neurological disorders |
| 06/29/2006 | CA2590246A1 Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics |
| 06/29/2006 | CA2590155A1 Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders |
| 06/29/2006 | CA2589988A1 Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride |
| 06/29/2006 | CA2589877A1 Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| 06/29/2006 | CA2589827A1 Mitotic kinesin inhibitors |
| 06/29/2006 | CA2589779A1 Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors |
| 06/29/2006 | CA2589773A1 Pyridine carboxamide derivatives for use as anticancer agents |
| 06/29/2006 | CA2589764A1 Amide derivatives |
| 06/29/2006 | CA2589748A1 Heterocyclic compounds as ccr2b antagonists |
| 06/29/2006 | CA2589671A1 1-aminocyclohexane-derivatives for the treatment of multiple sclerosis emotional lability and pseudobulbar affect |
| 06/29/2006 | CA2589667A1 Vitamin d receptor modulators |
| 06/29/2006 | CA2589664A1 Vitamin d receptor modulators |
| 06/29/2006 | CA2589648A1 Fused pyrazole derivatives and methods of treatment of metabolic-relateddisorders thereof |
| 06/29/2006 | CA2589629A1 Quinoline tachykinin receptor antagonists |
| 06/29/2006 | CA2589367A1 Sulfonyl amino cyclic derivatives and use thereof |
| 06/29/2006 | CA2589331A1 Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin |
| 06/29/2006 | CA2589133A1 Quaternary ammonium salts as m3 antagonists |
| 06/29/2006 | CA2588966A1 Cladribine regimen for treating multiple sclerosis |
| 06/29/2006 | CA2588921A1 Pyrrolidine inhibitors of iap |
| 06/29/2006 | CA2588911A1 Therapeutic nutrient compositions or combinations and methods of their use |
| 06/29/2006 | CA2588220A1 Heteroaromatic derivatives useful as anticancer agents |
| 06/29/2006 | CA2588037A1 Indazole-carboxamide compounds |
| 06/29/2006 | CA2588028A1 Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2c adrenoreceptor antagonists |
| 06/29/2006 | CA2587664A1 Compounds with kv4 ion channel activity |
| 06/29/2006 | CA2586973A1 Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs |
| 06/29/2006 | CA2586582A1 3,3'-diindolylmethane immune activating compositions |
| 06/29/2006 | CA2585372A1 Preventive or therapeutic agent for glaucoma |
| 06/29/2006 | CA2584295A1 Spiro-2, 4-pyrimidinediamine compounds and their uses |
| 06/28/2006 | EP1674575A2 Ligand for herpes simplex virus entry mediator and methods of use |
| 06/28/2006 | EP1674574A1 Methods for Regulating Hematopoiesis using CpG-Oligonucleotides |
| 06/28/2006 | EP1674564A1 Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor |
| 06/28/2006 | EP1674470A1 Sulfonamido-macrocycles as Tie2 inhibitors |
| 06/28/2006 | EP1674469A1 Sulfonamido-macrocycles as Tie2 inhibitors |
| 06/28/2006 | EP1674468A1 Polymorphs of clopidogrel hydrobromide |
| 06/28/2006 | EP1674467A1 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| 06/28/2006 | EP1674466A1 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors |
| 06/28/2006 | EP1674464A1 Novel thrombin inhibitors |
| 06/28/2006 | EP1674463A1 Rabeprazole sodium salt in crystalline hydrate form |
| 06/28/2006 | EP1674457A1 Derivatives of squaric acid with anti-proliferative activity |
| 06/28/2006 | EP1674456A2 Substituted alpha-halo-beta-keto-pyridinylpropanoates |
| 06/28/2006 | EP1674454A1 SUBSTITUTED 2-AMINO- 1,2,4 TRIAZOLO 1,5-a PYRIMIDINE DERIVATIVE AND USE THEREOF |
| 06/28/2006 | EP1674452A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
| 06/28/2006 | EP1674399A1 Use of a container made of a plastic material containing an inorganic additive |
| 06/28/2006 | EP1674112A1 Compositions comprising an inhibitor of an acrab-like efflux pump for reducing microbial resistance to drugs |
| 06/28/2006 | EP1674108A2 Osteoporosis treatment |
| 06/28/2006 | EP1674105A1 Ready to use gemcitabine solutions and concentrates |
| 06/28/2006 | EP1674104A1 Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV |
| 06/28/2006 | EP1674103A1 Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands |
| 06/28/2006 | EP1674102A1 Use of flibanserin in the treatment of sexual disorders |
| 06/28/2006 | EP1674101A1 Cinnamates of Benzo[b]pyrano[3,2-h]acridin-7-one, process for preparation thereof and their pharmaceutical composition |
| 06/28/2006 | EP1674100A1 Angiogenesis inhibitor |
| 06/28/2006 | EP1674099A1 Therapeutic combination of amlodipine and benazepril / benazeprilat |
| 06/28/2006 | EP1674098A1 Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| 06/28/2006 | EP1674097A1 Compounds effecting glucokinase |
| 06/28/2006 | EP1674096A2 Hypoglycemics comprising organic zinc (II) complexes |
| 06/28/2006 | EP1674095A1 Phototherapy compositions |
| 06/28/2006 | EP1674094A1 Composition containing retinoic acid nanoparticles coated with polyvalent metal inorganic salt |
| 06/28/2006 | EP1674093A1 Method of controlling particle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method |
| 06/28/2006 | EP1674092A1 Amino acid compositions |
| 06/28/2006 | EP1674091A1 Ophthalmic composition for treating lacrimal disorders |
| 06/28/2006 | EP1674090A1 Early insulin secretion promoter |
| 06/28/2006 | EP1674089A1 Accelerator for initial insulin secretion |
| 06/28/2006 | EP1674088A1 Jelly preparation containing biguanide medicine |
| 06/28/2006 | EP1674087A1 Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists |
| 06/28/2006 | EP1674084A2 Extended release oral dosage composition |
| 06/28/2006 | EP1674079A2 Pressurised metered dose inhalers (MDI) |
| 06/28/2006 | EP1674068A1 Dermal penetration enhancers and drug delivery systems involving same |
| 06/28/2006 | EP1673988A1 Micronutrient formulation for cognitive & mood benefits |